Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YL242 + pembrolizumab + 5-fluorouracil
- Development stage
- Unknown
- Lead developer
- MediLink Therapeutics
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
YL242 + pembrolizumab + 5-fluorouracil is a combination therapy being evaluated for the treatment of advanced solid tumors. YL242 is a novel, non-internalized antibody-drug conjugate (ADC) developed by MediLink Therapeutics using the proprietary TMALIN® platform. It consists of an anti-VEGF antibody conjugated to a DNA topoisomerase I inhibitor payload (C24) via a protease-cleavable tripeptide linker. This combination pairs the anti-angiogenic and cytotoxic effects of YL242 with the immune checkpoint inhibition of pembrolizumab (a PD-1 inhibitor) and the antimetabolite activity of 5-fluorouracil. The regimen is designed to provide dual anticancer activity through both anti-angiogenesis and cytotoxicity from the extracellularly released payload in the tumor microenvironment, while simultaneously enhancing the immune response. It is currently in Phase 1/2 clinical trials for indications including non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, and gastric/gastroesophageal junction cancers.
- Other names
- YL242 + pembrolizumab + 5-FU
02
Targets
UNG (Uracil-DNA glycosylase)VEGFA (Vascular endothelial growth factor A)UPP1 (Uridine phosphorylase)TS (Thymidylate synthase)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on YL242 + pembrolizumab + 5-fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YL242 + pembrolizumab + 5-fluorouracil.